To Get Full Access :

Defencath

Defencath is a catheter lock solution used in adult dialysis patients with central venous catheters. It helps prevent bloodstream infections by combining antimicrobial and anti-clotting effects.

The information outlined in the molecule details section below would help you evaluate Para IV filing opportunities early to secure a first-to-file advantage.

Molecule Details :

  • Molecule Name :

    Taurolidine And Heparin
  • Innovator :

    CORMEDIX INC
  • Approval Date :

    15-Nov-23
  • NCE-1 Date :

    15-Nov-27
  • NCE Date :

    15-Nov-28
  • Dosage Form :

    Single Dose Vial To Instill In Central Venous Catheters
  • Strength :

    3,000 UNITS/3ML (1,000 UNITS/ML);40.5MG/3ML (13.5MG/ML), 5,000 UNITS/5ML (1,000 UNITS/ML);67.5MG/5ML (13.5MG/ML)
  • Therapeutic Category :

    Antimicrobial And Anticoagulant
  • Revenue ($M) :

    NA

Year-wise Projected Sales ($M) :

  • 2025 :

    165
  • 2026 :

    247
  • 2027 :

    274
  • 2028 :

    333
  • 2029 :

    341
  • 2030 :

    400
  • 2031 :

    457
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Choose Spring Bio Solution?

Supported 1000+ Clinical Trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO Services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions 


Login With

For full access Sign-up / Sign-in using below Methods:

By continuing, you agree to our Terms & Conditions and Privacy Policy. You can review them anytime.

Are you sure want to logout from NCE Grid?